Table 4.
Univariate logistic regression model predicting the risk of oligometastatic prostate cancer with toxicity vs. no toxicity.
| β ± s.e. | Odds ratio | p-Value | |
|---|---|---|---|
| Age (years) Age (Ref: <60) 60–69 70–79 >80 |
−0.032 ± 0.03 −17.1 ± 1,697 −16.5 ± 1,697 −17.0 ± 1,697 |
0.97 3.83e−8 6.79e−8 4.12e−8 |
0.3 >0.99 >0.99 >0.99 |
| Race (Ref: White) Black Other |
0.24 ± 0.53 0.24 ± 1.03 |
1.27 1.27 |
0.7 0.8 |
| BMI BMI (Ref: 18.5–24.9) 25.0–29.9 30.0–34.9 35.0–39.9 ≥40.0 |
−0.034 ± 0.04 −0.43 ± 0.63 −0.12 ± 0.70 1.39 ± 1.23 −1.66 ± 1,385 |
0.97 0.65 0.89 4.00 6.39e−8 |
0.4 0.5 0.9 0.3 0.99 |
| Pretreatment PSA | 0.016 ± 0.01 | 1.02 | 0.1 |
| PSA response (Ref: Yes) No |
−0.22 ± 0.60 | 0.8 | 0.7 |
| Current ADT (Ref: No) Yes |
0.92 ± 0.56 | 2.51 | 0.1 |
| Prior treatment Radical prostatectomy (Ref: No) Yes Prostate SBRT (Ref: No) Yes |
0.22 ± 0.52 −0.17 ± 1.03 |
1.25 0.84 |
0.7 0.9 |
| Pre-SBRT imaging (Ref: PSMA) Axumin MRI/CT |
−0.27 ± 0.50 −0.22 ± 0.77 |
0.76 0.80 |
0.6 0.8 |
| Hormone sensitivity (Ref: Castrate sensitive) Castrate resistant |
1.77 ± 0.83 | 5.85 | 0.03 |
| Target volume (Ref: No boost) Boost |
−0.12 ± 0.47 | 0.89 | 0.8 |
| # of lymph nodes | 0.20 ± 0.08 | 1.22 | 0.008 |
| Location of radiation (Ref: Abdomen) Abdomen + pelvis Pelvis |
−0.14 ± 0.62 −1.3 ± 0.60 |
0.87 0.27 |
0.8 0.03 |
BMI, body mass index; PSA, prostate-specific antigen; ADT, androgen deprivation therapy; SBRT, stereotactic body radiotherapy.
The bolded values indicate that they are statistically significant.